➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Mallinckrodt
AstraZeneca
Baxter
Boehringer Ingelheim
Express Scripts
Dow

Last Updated: January 23, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,431,615

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,431,615 protect, and when does it expire?

Patent 8,431,615 protects INCIVEK and is included in one NDA.

This patent has twenty patent family members in thirteen countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.

Summary for Patent: 8,431,615
Title:Dose forms
Abstract: The present invention relates to antiviral therapies and compositions for treating or preventing Hepatitis C infections in patients and relates to other methods disclosed herein. The invention also relates to kits and pharmaceutical packs comprising compositions and dosage forms. The invention also relates to processes for preparing these compositions, dosages, kits, and packs.
Inventor(s): Chu; Hui-May (Natick, MA), Ette; Ene (Framingham, MA), McNair; Lindsay (Allston, MA), Alam; John (Cambridge, MA)
Assignee: Vertex Pharmaceuticals Incorporated (Cambridge, MA)
Application Number:11/264,746
Patent Claim Types:
see list of patent claims
Compound;

Drugs Protected by US Patent 8,431,615

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Vertex Pharms INCIVEK telaprevir TABLET;ORAL 201917-001 May 23, 2011 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,431,615

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2005302361   Start Trial
Canada 2585647   Start Trial
China 101068547   Start Trial
China 102988365   Start Trial
European Patent Office 1819336   Start Trial
European Patent Office 2500021   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Dow
Mallinckrodt
Colorcon
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.